Structure Therapeutics (GPCR) Jefferies London Healthcare Conference 2024 summary

Key company developments and strategic focus

• Expanded management team and released positive phase II-A data for chronic weight management in 2024.

• Announced phase II-B plans for GSBR-1290, with a focus on small molecule GLP-1s for broader accessibility and scalability.

• Manufacturing capacity exceeds 6,000 metric tons, supporting up to 120 million patients at a 120 mg dose.

• Emphasis on fixed dose combinations, leveraging a structure-based drug discovery platform.

• Well-financed with over $900 million in cash, supporting milestones through 2027.

Clinical trial progress and data highlights

• Phase II-A data showed 6.2%-6.9% placebo-adjusted weight loss at 12 weeks; 33% of participants lost over 10% body weight.

• Low study discontinuation rates (5%-11%) compared to 33%-54% in similar studies.

• Phase II-B ACCESS and ACCESS-2 studies initiated, targeting 300 participants with dose range finding up to 240 mg.

• Phase II-B designed for seamless transition to phase III, with late-stage data expected by end of 2025.

• Efficacy at 120 mg expected to match top competitors; higher doses (180, 240 mg) targeted for incremental 1.5%-2% weight loss improvement.

Pipeline and combination therapy strategy

• GSBR-1290 positioned as a chronic weight management monotherapy, with rapid movement toward combination studies.

• Oral amylin small molecule program to declare first development candidate (DC) by year-end, with potential for muscle mass preservation and improved tolerability.

• Combination of GLP-1 and amylin molecules demonstrated synergistic weight loss effects in recent data.

• Additional pipeline assets include GIP, GCG, apelin, and LPA1, with LPA1 phase I data expected in 2025.

• Cash runway supports ongoing and future clinical milestones, including multiple DCs and combination studies.